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1078–5Objectives. Adipose tissue is able to secrete a variety of active mediators into the circulation. One of these is Interleukin 6
(IL6). IL6 may play a causal role in the development of atherosclerosis. It has therefore been suggested that IL6 may form
part of the link between obesity and vascular disease. The aim of this study was to quantify the relative IL6 expression in
adipose tissue compared to other tissues.
Methods. Tissue (vein, fat, muscle, blood) was collected from 32 patients undergoing varicose vein surgery. RNA was
extracted and mRNA measured using RT-PCR relative quantification. The mean relative IL6 mRNA levels were compared
between tissues using the Mann Whitney U test and the independent t-test. Tissue levels were compared for individuals
using the Wilcoxon signed rank test.
Results. Mean relative IL6 mRNA levels (mean SEM) were significantly greater in adipose tissue 44.8 16.1 than in
other tissues (leukocytes 1.1 0.3, vein 2.0 0.8, muscle 0.06 0.03: p< 0.001). mRNA expression levels were also
significantly higher in fat than in all other tissue types in individuals (p< 0.001).
Conclusions. IL6 mRNA expression is significantly higher in adipose than in many other tissues known to express IL6.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Atherosclerosis is the most common cause of death in
the western world.1 Obesity, a major risk factor for ar-
terial disease, has undergone a rapid increase in prev-
alence in recent years.2,3 This may result in an
increased incidence of atherosclerosis in the future.4
It is therefore important to explore the mechanisms
underlying the association of obesity and vascular
disease.
Interleukin 6 (IL6) is a pro-inflammatory cytokine.
Raised circulating IL6 levels are associatedwith arterial
disease and as well as arterial disease progression.5,6
Levels of plasma IL6 correlate with sub-clinical ath-
erosclerosis7 and appear to predict future risk ofsponding author. S. Sonnenberg, Human Genetics Division,
Building, MP 808, Southampton General Hospital, Tremona
Southampton SO16 6YD, UK.
address: sabinesonnenberg@tiscali.co.uk
884/000314+ 06 $34.00/0  2007 European Society for Vasculacardiovascular events.5 These findings have led to the
hypothesis that IL6 may form part of the causal chain
in arterial disease development and progression. In
addition, IL6 may influence outcome from surgical
treatment as raised levels of IL6 are associated with
an increased systemic inflammatory response and
risk of multi-organ failure following aortic surgery.8
IL6 may further play a role in the long term outcome
from vascular surgery determined by the development
of intimal hyperplasia leading to graft failure.9
It has become apparent that adipose tissue has an
important endocrine function and is able to release a
variety of active mediators into the circulation,10 one
of them IL6.11 Plasma levels of IL6 are positively associ-
ated with body mass index12e14 and adiposity and
decrease with weight loss.12,14,15 It has been suggested
that obesity represents a low grade inflammatory state
and that the associated increase in circulating IL6 may
affect the vascular endothelium, explaining the link
between obesity and atherosclerosis.16e19r Surgery. Published by Elsevier Ltd. All rights reserved.
315Level of Ex Vivo Interleukin 6 Expression in Human Peripheral FatIL6 is expressed in a variety of tissues apart from
adipose tissue including muscle, vascular wall and
blood.20 It is unclear to what extent the individual
tissues contribute to the total circulating IL6 levels.
We thus sought to quantify IL6 mRNA in tissues
known to produce IL6 (adipose tissue, vein, skeletal
muscle and leukocytes), in a series of human subjects.
Subjects suffering from vascular disease were ex-
cluded, as atheromatous disease itself can affect IL6
RNA levels in certain tissues21 and could therefore
mask or exaggerate the effect of tissue type on gene
expression.Methods
Subjects
Following ethic consent (Southampton & South West
Hampshire Research Ethics Committees (REC) Refer-
ence: 040/04/w), 32 consecutive subjects with Amer-
ican Society of Anaesthesiologists (ASA) grades I or
II who were due to undergo routine varicose vein sur-
gery were recruited to the study. Excluded were those
with a history of arterial, malignant or acute inflam-
matory disease and those currently taking steroids.
Patient age, body mass index, ethnic origin, past med-
ical history, medication and smoking habits were
documented.Tissue collection and RNA extraction
Vein, blood, skeletal muscle (pectineus) and periph-
eral adipose tissue (128 tissue samples) were collected
from all subjects. Tissues were immediately sub-
merged in RNAlater (Sigma-Aldrich) to maintain
the in vivo RNA profile. Blood samples were collected
using PAXgene Kit (PreAnalytiX).
RNAwas extracted from all the collected tissues us-
ing a modified TRI-Reagent (Sigma-Aldrich) method.
Leukocyte RNA was extracted using the PAXgene
Kit. RNA was quantified using spectrophotometry.
For reverse transcription, 500 ng of total RNAwas tran-
scribed into cDNA using random hexamer primers
(PrimerDesign Ltd, http://www.primerdesign.co.uk/)
and M-MLV reverse transcriptase (PrimerDesign Ltd,
http://www.primerdesign.co.uk/).Real time PCR analysis
Real time polymerase chain reaction (PCR) analysis
was used to measure IL6 mRNA expression in 128
samples using the LightCycler 480 Real Time PCRSystem. The IL6 assay consisted of pre-designed
primers and fluorescein labelled (FAM) TaqMan probe
and quencher (AppliedBiosystems: Hs00174131_m1).
Analysis was performed as relative quantification with
reference to the housekeeping gene glyceraldehye-
3-phosphate dehydrogenase (GAPDH). The assay
for GAPDH used pre-designed primers and a FAM
hydrolysis probe and quencher (Universal Probe
Library Probe #60, Roche). Both target and house-
keeping assays were cDNA specific. Relative quantifi-
cation data was analysed using ROCHE LC480
Relative Quantification Software. This software uses
a standard curve to account for differences in effi-
ciency between reference and target gene assay and
allows normalisation to a calibrator sample to account
for differences between individual runs. Reactions
were performed in duplicate with a standard curve
in each run.Statistical analysis
Only samples with relative quantification data for all
four tissue types were included in the statistical
analysis. Statistical analysis was performed using
‘statistical package for the social sciences’ (SPSS)
software. A p-value of less than 0.0125 was consid-
ered significant. The normalised concentration ratios
were grouped together according to tissue type. The
normalised concentration ratio was not normally dis-
tributed in any of the tissues. Therefore to test for
significant difference in expression between tissue
types, the Mann-Whitney U test was applied. The
data was also logarithmically transformed allowing
reanalysis using the independent t-test with equal
variance not assumed.
Normalised concentration values in the four tissues
were then matched for each subject and variation of
IL6 expression between tissues was assessed for the
individual patient by Wilcoxon signed rank test.
To test for a correlation between IL6 expression in
adipose tissue and BMI the Spearman rank correlation
was calculated.Results
Patients all were of European origin. Out of the 32 re-
cruited patients, normalised concentration ratios were
available for all four tissues in 21 patients i.e. 84 tissue
samples. Out of the 21 subjects (12 female, 9 male) five
were cigarette smokers and ten took regular medica-
tion: nifedipine, hydrochlorothiazide, aspirin, salbuta-
mol, omeprazole, allopurinol were taken by one
patient each. Two patients took amitriptyline andEur J Vasc Endovasc Surg Vol 35, March 2008
Fig. 1. Individual values for the logarithm of the normalised
concentration ratio of IL6 expression in different tissues.
There are 21 samples represented in each tissue type.
316 S. Sonnenberg et al.two took an oral contraceptive pill. The average age of
our patients was 47 years (range 24e69 years).
Expression of IL6 mRNA in adipose tissue was
significantly higher in adipose tissue than in all other
tissue types examined (Table 1 & Fig. 1). The mean -
 SEM normalised concentration ratio of IL6 com-
pared with the housekeeping gene GAPDH was
44.8 16.1 (median¼ 14.9) for adipose tissue;
1.1 0.3 (median¼ 0.8) for leukocytes; 2.0 0.8 (me-
dian¼ 0.4) for vein and 0.06 0.03 (median¼ 0.03)
for muscle. Median and mean levels of IL6 mRNA
were significantly higher in adipose tissue than in
all other tissues (Mann Whitney U: (two-tailed)
p< 0.001; independent t-Test: (two-tailed) p 0.001).
In the individual subject, levels of IL6 mRNA
were also significantly higher in fat when compared
to all other tissues for the same subject (Wilcoxon
signed rank test p< 0.001) (Fig. 2). IL6 mRNA level
in adipose tissue was on average 55.0, 35.8 and
697.3 times higher than IL6 expression in leuko-
cytes, vein and muscle respectively in the same
individual.
BMI was recorded in 20 patients. The mean
SEM body mass index (BMI) was 27.3 0.9. There
was no significant correlation between IL6 expres-
sion in adipose tissue and BMI (Spearman correla-
tion coefficient¼ 0.24; significance (2-tailed)¼ 0.31)
i.e. increase in BMI did not associate with an in-
crease in relative IL6 RNA expression or vice versa
(Fig. 3).Table 1. Relative levels of interleukin 6 mRNA in four different




ratio by tissue type
Adipose Leukocytes Vein Muscle
10 14.90 1.49 0.40 0.01
13 6.50 0.97 0.21 0.05
14 2.49 0.76 0.24 0.00
15 108.00 1.81 7.56 0.03
17 98.16 0.72 0.82 0.02
18 303.00 6.11 15.52 0.72
19 13.23 0.40 5.21 0.09
24 38.42 0.47 0.38 0.04
25 6.17 1.37 1.63 0.04
26 11.97 1.39 0.29 0.02
28 174.00 0.46 0.66 0.02
29 27.61 0.83 0.24 0.04
30 21.85 1.52 4.34 0.08
31 2.38 0.60 1.28 0.02
34 11.16 1.53 0.22 0.00
35 5.80 0.90 1.65 0.00
36 16.63 0.66 0.64 0.04
37 4.60 0.64 0.16 0.01
38 57.38 0.24 0.00 0.04
41 15.07 0.35 0.23 0.03
43 2.48 0.85 0.41 0.05
Eur J Vasc Endovasc Surg Vol 35, March 2008Discussion
To date, comparative data on IL6 expression has been
available in the form of the gene expression atlas.22
However vein, muscle and adipose tissue are not
represented in the atlas. Furthermore, the geneFig. 2. Logarithm of IL6 mRNA normalised concentration
ratio for individual patients in all four tissue types. In every
patient adipose tissue shows the highest values for IL6
mRNA levels.
Fig. 3. Graph showing correlation of adipose IL6 RNA ex-
pression with body mass index. The trend line shows
a very weakly positive correlation which is not significant
(p¼ 0.32).
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tained tissues which originate from different individ-
uals. There is large variation in IL6 expression in
individuals, partially related to variables such as
smoking, medication and age, which can affect the
result.23e25 This study uses paired tissue samples
from one individual, taken at the same time point
thereby reducing the effect of these confounding vari-
ables giving a more accurate insight into the effect of
tissue type on IL6 gene expression.
Our data shows that adipose tissue expresses sig-
nificantly more IL6 mRNA than the other tissues ex-
amined, suggesting that increased adiposity might
influence circulating IL6 levels and thus vascular
risk and treatment outcome. These data are consistent
with a 23% fall in plasma IL6 levels associated with
33% weight loss in the very obese.15 Indeed, arterio-
venous differences in plasma IL6 levels across an
abdominal subcutaneous tissue bed suggest that up
to 30% of plasma IL6 may be derived form adipose
tissue depending on BMI.26 This study measured
IL6 RNA expression in adipose tissue relative to
a housekeeping gene rather than plasma IL6 levels.
Therefore the lack of correlation between BMI and
adipose tissue expression is not surprising, as the in-
crease in plasma IL6 seen in obesity is likely to relate
to increase in total body fat mass. However, it is pos-
sible that obesity further leads to increased IL6 ex-
pression through a change in the cell composition of
adipose tissue with a relative increase in those cells
that are mainly responsible for the expression of IL6.Only 10% of IL6 derived from adipose tissue cell cul-
ture arises from adipocytes.27 Other sources of IL6 in
adipose tissue are stromal-vascular cells and macro-
phages, with macrophages thought to be the main con-
tributors.28,29 Adipose tissuemacrophage infiltration is
increased in obese subjects30 and decreases during
weight loss.31 Therefore the relative IL6 expression in
adipose tissue may increase with adiposity beyond
a pure volume effect. This study does not support
this view, as there was no significant correlation
between BMI and IL6 expression in adipose tissue.
However, correlation was only tested in 20 samples.
It is possible that variables such as age, smoking or
medication masked any effect of cell composition on
adipose IL6 expression. Further studies may provide
better insight.
A number of patients had considerably higher IL6
expression compared to other subjects in some tissues.
Possible reasons include unidentified genetic variables
or variables such age, smoking, medication or undiag-
nosed infection at the time of sample collection. The
design of the study aimed to reduce the influence of
such variables on the outcome measure of relative tis-
sue expression by performing intra-individual com-
parison i.e. all four samples came from the same
individual, therefore all samples were subject to the
same unidentified variable. However, it can not be
excluded that some variables may affect individual
tissues differently. Investigating potential causes for
higher expression in some patients requires an inter-
individual comparison which may be difficult to inter-
pret in a relatively small sample set. Such a comparison
was therefore not performed.
It is not possible to deduce the exact percentage
adipose tissue contributes to the circulating IL6,
from relative IL6 mRNA levels measured in this
study. Various steps exist that exert post transcrip-
tional control, i.e. not all mRNA will be translated
into protein, and these post-transcriptional changes
may vary between tissue types. In addition, protein
production within the cell may not translate into
equivalent secretion of the protein, as an intracellular
signalling pathway for IL6 is thought to exist.32 It is
therefore possible that a proportion of IL6 will never
leave the cell. In addition, some of the IL6 secreted by
adipose tissue may act in a paracrine manner and
therefore remain within the tissue rather than enter
the circulation, though release of IL6 has been demon-
strated from peripheral fat.17 Despite these reserva-
tions, it is thought that the circulating levels of IL6
are mainly regulated at the level of gene expression,33
making it likely that the difference in mRNA expres-
sion will be reflected in tissue contribution to IL6
plasma levels.Eur J Vasc Endovasc Surg Vol 35, March 2008
318 S. Sonnenberg et al.Adipose tissue expressed forty times as much IL6
mRNA as leukocytes in this study. However the per-
centage contribution of adipose tissue to plasma IL6
levels depends on levels of adiposity, thus its’ relative
importance is decreased in lean subjects. In addition
IL6 secreted by circulating leukocytes will immedi-
ately contribute to IL6 plasma levels unlike adipose
derived IL6 which may remain within the tissue itself.
Thus leukocyte derived IL6 may play a more impor-
tant role in plasma levels then the figures for mRNA
expression suggest.
In this study the mean mRNA expression in fat tis-
sue was almost 700 times greater than the expression
in muscle. The transcription of IL6 in muscle as well
as net release from muscle has been shown to increase
following exercise.34,35 Although exercise also appears
to increase IL6 expression in adipose tissue, the in-
crease is relatively smaller than the one observed in
muscle. One would expect exercise to lead to a rela-
tively higher increase in contribution from muscle to
circulating IL6 levels.36 In addition, it has been shown
that IL6 release from muscle increases from the fasting
level following a high fat meal. In this study patients
presented to hospital following overnight rest and
overnight fast. The relative level of IL6 expression in
muscle in more active subjects and subjects in the
postprandial phase may therefore be higher than
demonstrated here.
It is known that visceral obesity constitutes a greater
risk factor for atherosclerosis than peripheral adipos-
ity.37 Studies examining site of production of circulat-
ing IL6 suggest a greater contribution from visceral
fat than from peripheral adipose tissue.27,38 This study
examined subcutaneous fat samples only. It is likely
that the relative contribution of visceral fat to systemic
IL6 is higher than the figures presented here, empha-
sising the importance of weight loss in decreasing
circulating levels of IL6.
Raised circulating IL6 levels are associated with the
development and progression of vascular disease as
well as negative outcome from surgery both in terms
of short term outcome and long term vascular graft
patency. The findings from this study suggest that
increase in adipose tissue mass has a distinct potential
to increase circulating IL6 levels, as adipose IL6
expression appears to be significantly higher than
expression in other tissues. Assessing whether this
forms a causal link between obesity and vascular dis-
ease, requires further research into the IL6/vascular
disease relationship. Studies utilising genetic varia-
tions in the IL6 gene are effective tools for exploring
the causal nature of the association between mediator
and disease. Such studies are likely to advance our
knowledge in the future.Eur J Vasc Endovasc Surg Vol 35, March 2008Conclusion
IL6 mRNA levels in human subjects are significantly
greater in adipose tissue than in other tissues known
to express IL6. It is therefore likely that IL6 expression
from adipose tissue has important paracrine, endo-
crine or inflammatory roles.Conflict of interest
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MRC and British Heart Foundation.References
1 GABAY C, KUSHNER I. Acute-phase proteins and other systemic
responses to inflammation. N Engl J Med 1999 Feb 11;340(6):
448e454.
2 Obesity: preventing and managing the global epidemic. Report
of a WHO consultation. World Health Organ Tech Rep Ser 2000;
894:iexii, 1e253.
3 DARVALL KA, SAM RC, SILVERMAN SH, BRADBURY AW, ADAM DJ.
Obesity and thrombosis. Eur J Vasc Endovasc Surg 2007 Feb;
33(2):223e233.
4 FERRONI P, BASILI S, FALCO A, DAVI G. Inflammation, insulin resis-
tance, and obesity. Curr Atheroscler Rep 2004 Nov;6(6):424e431.
5 RIDKER PM, RIFAI N, STAMPFER MJ, HENNEKENS CH. Plasma concen-
tration of interleukin-6 and the risk of future myocardial infarc-
tion among apparently healthy men. Circulation 2000 Apr 18;
101(15):1767e1772.
6 HUBER SA, SAKKINEN P, CONZE D, HARDIN N, TRACY R. Interleukin-
6 exacerbates early atherosclerosis in mice. Arterioscler Thromb
Vasc Biol 1999 Oct;19(10):2364e2367.
7 AMAR J, FAUVEL J, DROUET L, RUIDAVETS JB, PERRET B, CHAMONTIN B
et al. Interleukin 6 is associated with subclinical atherosclerosis:
a link with soluble intercellular adhesion molecule 1. J Hypertens
2006 Jun;24(6):1089e1095.
8 BOWN MJ, HORSBURGH T, NICHOLSON ML, BELL PR, SAYERS RD.
Cytokines, their genetic polymorphisms, and outcome after
abdominal aortic aneurysm repair. Eur J Vasc Endovasc Surg
2004 Sep;28(3):274e280.
9 KLOUCHE M, ROSE-JOHN S, SCHMIEDT W, BHAKDI S. Enzymatically
degraded, nonoxidized LDL induces human vascular smooth
muscle cell activation, foam cell transformation, and prolifera-
tion. Circulation 2000 Apr 18;101(15):1799e1805.
10 LAU DC, DHILLON B, YAN H, SZMITKO PE, VERMA S. Adipokines:
molecular links between obesity and atheroslcerosis. Am J Phys-
iol Heart Circ Physiol 2005 May;288(5):H2031eH2041.
11 MOHAMED-ALI V, FLOWER L, SETHI J, HOTAMISLIGIL G, GRAY R,
HUMPHRIES SE et al. Beta-adrenergic regulation of IL-6 release
from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol
Metab 2001 Dec;86(12):5864e5869.
12 DANDONA P, ALJADA A, BANDYOPADHYAY A. Inflammation: the link
between insulin resistance, obesity and diabetes. Trends Immunol
2004 Jan;25(1):4e7.
13 KERN PA, RANGANATHAN S, LI C, WOOD L, RANGANATHAN G. Adi-
pose tissue tumor necrosis factor and interleukin-6 expression
in human obesity and insulin resistance. Am J Physiol Endocrinol
Metab 2001 May;280(5):E745eE751.
14 ESCOBAR-MORREALE HF, VILLUENDAS G, BOTELLA-CARRETERO JI,
SANCHO J, SAN MILLAN JL. Obesity, and not insulin resistance, is
the major determinant of serum inflammatory cardiovascular
risk markers in pre-menopausal women. Diabetologia 2003
May;46(5):625e633.
319Level of Ex Vivo Interleukin 6 Expression in Human Peripheral Fat15 KOPP HP, KOPP CW, FESTA A, KRZYZANOWSKA K, KRIWANEK S,
MINAR E et al. Impact of weight loss on inflammatory proteins
and their associationwith the insulin resistance syndrome inmor-
bidly obese patients. Arterioscler Thromb Vasc Biol 2003 Jun 1;
23(6):1042e1047.
16 YUDKIN JS, KUMARI M, HUMPHRIES SE, MOHAMED-ALI V. Inflamma-
tion, obesity, stress and coronary heart disease: is interleukin-6
the link? Atherosclerosis 2000 Feb;148(2):209e214.
17 MOHAMED-ALI V, GOODRICK S, RAWESH A, KATZ DR, MILES JM,
YUDKIN JS et al. Subcutaneous adipose tissue releases interleu-
kin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocri-
nol Metab 1997 Dec;82(12):4196e4200.
18 RONTI T, LUPATTELLI G, MANNARINO E. The endocrine function of
adipose tissue: an update. Clin Endocrinol (Oxf) 2006 Apr;64(4):
355e365.
19 PLATA-SALAMAN CR. Cytokines and feeding. News Physiol Sci 1998
Dec;13:298e304.
20 BENNERMO M, HELD C, STEMME S, ERICSSON CG, SILVEIRA A, GREEN F
et al. Genetic predisposition of the interleukin-6 response to in-
flammation: implications for a variety of major diseases? Clin
Chem 2004 Nov;50(11):2136e2140.
21 SEINO Y, IKEDA U, IKEDA M, YAMAMOTO K, MISAWA Y, HASEGAWA T
et al. Interleukin 6 gene transcripts are expressed in human
atherosclerotic lesions. Cytokine 1994 Jan;6(1):87e91.
22 SU AI, COOKE MP, CHING KA, HAKAK Y, WALKER JR, WILTSHIRE T
et al. Large-scale analysis of the human and mouse transcrip-
tomes. Proc Natl Acad Sci USA 2002 Apr 2;99(7):4465e4470.
23 OLIVIERI F, BONAFE M, CAVALLONE L, GIOVAGNETTI S, MARCHEGIANI F,
CARDELLI M et al. The 174 C/G locus affects in vitro/in vivo
IL-6 production during aging. Exp Gerontol 2002 Jan;37(2e3):
309e314.
24 TREVELYAN J, BRULL DJ, NEEDHAM EW, MONTGOMERY HE,
MORRIS A, MATTU RK. Effect of enalapril and losartan on cyto-
kines in patients with stable angina pectoris awaiting coronary
artery bypass grafting and their interaction with polymor-
phisms in the interleukin-6 gene. Am J Cardiol 2004 Sep 1;
94(5):564e569.
25 HELMERSSON J, LARSSON A, VESSBY B, BASU S. Active smoking and
a history of smoking are associated with enhanced prostaglan-
din F(2alpha), interleukin-6 and F2-isoprostane formation in
elderly men. Atherosclerosis 2005 Jul;181(1):201e207.
26 MOHAMED-ALI V, PINKNEY JH, COPPACK SW. Adipose tissue as an
endocrine and paracrine organ. Int J Obes Relat Metab Disord
1998 Dec;22(12):1145e1158.
27 FRIED SK, BUNKIN DA, GREENBERG AS. Omental and subcutaneous
adipose tissues of obese subjects release interleukin-6: depotdifference and regulation by glucocorticoid. J Clin Endocrinol
Metab 1998 Mar;83(3):847e850.
28 CRICHTON MB, NICHOLS JE, ZHAO Y, BULUN SE, SIMPSON ER. Expres-
sion of transcripts of interleukin-6 and related cytokines by hu-
man breast tumors, breast cancer cells, and adipose stromal cells.
Mol Cell Endocrinol 1996 Apr 19;118(1e2):215e220.
29 WEISBERG SP, MCCANN D, DESAI M, ROSENBAUM M, LEIBEL RL,
FERRANTE Jr AW. Obesity is associated with macrophage accumu-
lation in adipose tissue. J Clin Invest 2003 Dec;112(12):1796e1808.
30 SPANGENBURG EE, SHOELSON SE, WEIGERT C, LEHMANN R,
SCHLEICHER ED, JANSSON JO et al. Interleukin-6 does/does not
have a beneficial role in insulin sensitivity and glucose homeo-
stasis. J Appl Physiol 2007 Feb;102(2):820e823.
31 CANCELLO R, HENEGAR C, VIGUERIE N, TALEB S, POITOU C, ROUAULT C
et al. Reduction of macrophage infiltration and chemoattractant
gene expression changes in white adipose tissue of morbidly
obese subjects after surgery-induced weight loss. Diabetes 2005
Aug;54(8):2277e2286.
32 VOYLE RB, RATHJEN PD. Regulated expression of alternate tran-
scripts from the mouse oncostatin M gene: implications for inter-
leukin-6 family cytokines. Cytokine 2000 Feb;12(2):134e141.
33 CASTELL JV, GEIGER T, GROSS V, ANDUS T, WALTER E, HIRANO T et al.
Plasma clearance, organ distribution and target cells of interleu-
kin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem 1988
Nov 1;177(2):357e361.
34 OSTROWSKI K, ROHDE T, ZACHO M, ASP S, PEDERSEN BK. Evidence
that interleukin-6 is produced in human skeletal muscle during
prolonged running. J Physiol 1998 May 1;508(Pt 3):949e953.
35 STEENSBERG A, VAN HALL G, OSADA T, SACCHETTI M, SALTIN B,
KLARLUND PB. Production of interleukin-6 in contracting human
skeletal muscles can account for the exercise-induced increase in
plasma interleukin-6. J Physiol 2000 Nov 15;529(Pt 1):237e242.
36 KELLER C, KELLER P, MARSHAL S, PEDERSEN BK. IL-6 gene expres-
sion in human adipose tissue in response to exerciseeeffect of
carbohydrate ingestion. J Physiol 2003 Aug 1;550(Pt 3):927e931.
37 ECKEL RH, GRUNDY SM, ZIMMET PZ. The metabolic syndrome.
Lancet 2005 Apr 16;365(9468):1415e1428.
38 TANKO LB, BRUUN JM, ALEXANDERSEN P, BAGGER YZ, RICHELSEN B,
CHRISTIANSEN C et al. Novel associations between bioavailable es-
tradiol and adipokines in elderly women with different pheno-
types of obesity: implications for atherogenesis. Circulation
2004 Oct 12;110(15):2246e2252.
Accepted 1 October 2007
Available online 26 December 2007Eur J Vasc Endovasc Surg Vol 35, March 2008
